Mainstay Medical Announces Two-Year Outcomes from RESTORE Clinical Trial of ReActiv8®

Contributed by: Business Wire

Tags

Medical Devices

Health

Neurology

Health Technology

Managed Care

Clinical Trials

Mainstay Medical Holdings plc

More Like This

Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8®

The long-term responses across pain, disability, and health-related quality of life measures are shown in the following graphs. (Graphic: Business Wire)

Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up

Mainstay Medical Announces Publication of Clinical Results Comparing Older Patients and Younger Patients

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield

Mainstay Medical Announces US$125 Million Equity Financing Transaction

Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv8

Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on ReActiv8® Restorative Neurostimulation SystemTM